Microba life sciences and ginkgo bioworks announce partnership to discover novel live biotherapeutics

Partnership will leverage ginkgo's high throughput screening capabilities to identify potential therapeutic candidates for autoimmune diseases in microba's extensive strain bank brisbane, australia and boston , april 4, 2022 /prnewswire/ -- microba life sciences (asx:map), a precision microbiome science company, and ginkgo bioworks  (nyse: dna), the leading horizontal platform for cell programming, today announced a partnership to identify single-strain, live bacteria product (lbp) candidates against autoimmune diseases. the collaboration aims to build on microba's precision approach to lbp development with an in-depth evaluation of the company's strains using ginkgo's high throughput, automated screening capabilities.
DNA Ratings Summary
DNA Quant Ranking